AstraZeneca (AZN) announced its plans to spend $1.5 billion to build its first manufacturing facility in Singapore. Once built, it will be the company’s first facility to cover the full manufacturing process for its antibody drug conjugates (ADCs) portfolio at a commercial scale.ADCs are next-generation treatments that target cancer cells by delivering highly potent cancer-killing agents through a targeted antibody.AstraZeneca is building the manufacturing site to ensure a safe and reliable supply of ADCs. ...